In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck's Deal Focus

Executive Summary

Merck & Co. Inc.'s recovery drive involves changing every aspect of its business, and doing so urgently. That urgency applies to partnering, too: In March 2006, the giant announced three new deals, one with NicOx on a series of anti-hypertension compounds, one with Neuromed in pain and the third with Paratek Pharmaceuticals Inc. for a Phase I antibiotic. They mark a shift at Merck towards more clinical stage dealmaking.
Advertisement

Related Content

The Rise of Regional Dealmaking
The Rise of Regional Dealmaking
GSK's Risk-Sharing Deals to Compete with In-House R&D
NicOx Eyes Continued Comeback with Second Pfizer Deal
GSK's Risk-Sharing Deals to Compete with In-House R&D
NicOx Eyes Continued Comeback with Second Pfizer Deal
The Winners Post-Vioxx: Merck's Product-Focused Biotechs
The Winners Post-Vioxx: Merck's Product-Focused Biotechs
Merck Opens Up to Europe
NicOx/AstraZeneca: Transparency vs. Partnering

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002749

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel